Posts tagged ‘Biotech Marketing Consultant’
Pieter Droppert has prepared a short (2 minute) video review of BIO 2011, in which he notes that one of the major themes of the meeting was facilitating partnering, licensing & business development discussions between pharmaceutical and biotechnology companies.
Astra Zeneca tweeted that they had 500 partnering discussions planned, a number that is perhaps not so surprising in light of their pipeline and patent cliff over the next few years.
Another major focus of BIO was the marketing of biotechnology regions that takes place in the exhibit hall and at satellite events. Pieter has written in more detail on Biotech Strategy Blog about the session on innovation he attended, networking opportunities and the face of biotech social media.
His not too serious BIO 2011 video, that you can watch below, captures what he thought of the meeting as a first-time attendee.
We wish our Canadian clients a Happy Canada Day today and our United States clients an enjoyable Independence Day weekend. Icarus Consultants will be open for business again on Tuesday, July 5th.
One of the rate limiting steps in bringing new drugs to market is the time to accrue patients into clinical trials for registration. As the use of social media continues to evolve in the pharmaceutical industry, one area where it may have an impact is to educate patients about clinical research, and share information on trials that are enrolling.
Pieter Droppert on Biotech Strategy Blog looks at the use of social media in cancer treatment. It is estimated that only 3-5% of cancer patients participate in clinical trials.
Using Storify, a new online tool that aggregates information across various social media such as Twitter, Facebook, YouTube, Pieter looks at how social media is being for clinical trial education and recruitment. You can read more on Biotech Strategy Blog.
The Food & Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) earlier this year published 5-year data on the number of approvals and applications for new molecular entities (NME) i.e. new products not previously approved.
Pieter Droppert on Biotech Strategy Blog analyzes this data and discusses what we can conclude from it. Pieter also shares his thoughts on some of the challenges facing the biotechnology industry in bringing new products to market, and some of the factors that may be key to success.
Sally Church, PhD our oncology new products expert, is passionate about making a difference to the lives of patients with cancer. She channels her many talents and energies into helping pharma and biotech companies assess the best targets for their new products. It’s a job that requires science, marketing strategy and commercial awareness; a unique blend of skills.
Sally’s recent post on Pharma Strategy Blog entitled “Accelerated approval and cancer drugs” considers how best to bring new cancer drugs to market? Should promising oncology new products go from phase 2 clinical trials to market without the need for a large and expensive phase 3 registration study? If so, what happens when the data doesn’t pan out as happened with Roche/Genentech’s bevacizumab (Avastin) in breast cancer?
You can read more about Sally’s thoughts on Pharma Strategy Blog.
Icarus Consultants is a marketing strategy consulting company to biotechnology, pharmaceutical and life science companies. We don’t offer marketing communications services.
Source: Wikipedia
However, we like to keep our finger on the pulse of the market, so read with interest the recent United States Supreme Court decision in Matrixx Initiatives, Inc. v. Siracusano that involved a failure of Matrixx to share adverse event information with investors.
You may recall the issue of loss of smell associated with use of Zicam Cold Remedy Nasal Gel that contained zinc sulfate.
Matrixx argued that only statistically significant adverse events are material and need to be disclosed to investors, a position the Supreme Court disagreed with. In general terms, the Court held that adverse events that may be linked to a product that could impact a reasonable investor’s decision making need to be disclosed.
What’s the impact of this decision? The Matrixx decision will require companies and their PR agencies to think carefully about the need to include negative information as well as positive when making press releases. Clinical teams will need to talk to investor relations and marketing, something that may be a challenge in the silos of big pharma.
You can read more about this case, and a more in-depth analysis of Justice Sotomayor’s Supreme Court opinion on Biotech Strategy Blog.
It’s a word that one often hears, but did you know that 1 nanometer is a billionth of a meter or one seven-thousandth of the width of a red blood cell? Nanomaterials between 1nm and 100nm are unimaginably small.
As Pieter Droppert discusses today on Biotech Strategy Blog, innovation in nanotechnology is set to provide growth opportunities for life science, pharmaceutical, biotechnology, diagnostics and medical imaging companies.
We can expect to see new drug delivery mechanisms that enhance the efficacy of drugs for cancer, cardiovascular and infectious diseases, as well as new diagnostic tools and imaging agents.
You may not have realized it but nanotechnology is already used in 1000+ consumer products. Think about the titanium particles in your sunscreen as summer arrives.
You can read more about the impact of nanotechnology on Biotech Strategy Blog.
With the annual meeting of the European Assocation of Urology (EAU) starting in Vienna next week, Pieter Droppert’s post on Biotech Strategy Blog is very timely.
He discusses recent urology clinical research in which new urethras were successfully tissue engineered using cell culture techniques, and then implanted back into five young Mexican boys. The research is a world first and, while experimental, is further progress on the route towards regenerating organs such as kidneys and livers.
Pieter concludes: “Regenerative medicine is an exciting area to watch over the next few years.” As to what the impact this may have on the pharmaceutical and biotechnology industries, you’ll have to read the blog post.
When we do a market assessment or commercial landscape for a therapeutic area or new product, one of the things we look at is emerging new treatments or diagnostics. It’s important to understand the impact these may have on the market opportunity.
Recent research published in the AACR journal Clinical Cancer Research suggests that Engrailed-2 (EN2) may have potential as a biomarker for the diagnosis and treatment of prostate cancer (PC).
In a post on Biotech Strategy Blog, Pieter Droppert discusses the clinical data comparing EN2 to measurement of serum prostate specific antigen (PSA).
Amgen’s denosumab has been shown to reduce skeletal related events (SRE) but not improve overall survival (OS) in prostate cancer.
Icarus Consultants’ oncology new product development expert, Sally Church Ph.D looks at the role of RANKL signaling (the target of denosumab) and recent research on its role in the spread of cancer.
You can gain more insight on this interesting topic from Sally’s Pharma Strategy Blog post.